news
Dual antibodies effective against SARS-CoV-2 variants in animal study
In mice and hamsters, therapies made from two antibodies were found to be mostly effective against a range of SARS-CoV-2 variants.
List view / Grid view
AbbVie
news
Researchers treat diffuse intrinsic pontine glioma in mice
Researchers have treated diffuse intrinsic pontine glioma (DIPG), a fatal childhood brain cancer, in mice by targeting two metabolic pathways.
news
Lorenz Mayr joins Drug Discovery 2017 speaker lineup
Lorenz Mayr, esteemed Vice President and Global Head of Biological Reagents and Assay Development at AstraZeneca will be joining the expert speaker lineup for the launch conference on Drug Discovery. The event takes place on 27 and 28 April 2017 in London.
news
AbbVie and Bristol-Myers Squibb announce lung cancer clinical trials collaboration
25 July 2016 | By Niamh Louise Marriott, Digital Content Producer
AbbVie and Bristol-Myers Squibb Company today announced a clinical trial collaboration to evaluate the safety, tolerability and efficacy of AbbVie’s investigational biomarker-specific antibody drug conjugate Rova-T...
news
AbbVie and CytomX to co-develop Probody therapeutics
22 April 2016 | By Victoria White, Digital Content Producer
AbbVie and CytomX Therapeutics have entered into a collaboration to co-develop and co-commercialise Probody Drug Conjugates against CD71...
news
AbbVie and Argenx collaborate to develop ARGX-115
21 April 2016 | By Victoria White, Digital Content Producer
ARGX-115 targets the novel immuno-oncology target GARP, a protein believed to contribute to immunosuppressive effects of T-cells...
news
AbbVie announced as the latest Dementia Consortium partner
16 February 2016 | By Victoria White
AbbVie has been announced as the latest Dementia Consortium partner, joining MRC Technology, Alzheimer’s Research UK, Astex, Eisai and Lilly...
news
MD Anderson and AbbVie join forces to fight cancer
26 January 2016 | By Victoria White
The three-year collaboration agreement provides a framework for MD Anderson and AbbVie to efficiently choose and carry out preclinical and clinical studies evaluating new ideas in immuno-oncology...
news
F-star and AbbVie to develop bispecific antibodies in immuno-oncology
18 January 2016 | By Victoria White
Under the collaboration agreement, F-star and AbbVie will create Fcabs against two immuno-oncology targets and generate several mAb2 drug development candidates from these Fcabs...
news
Mimetas awarded funding for organ-on-a-chip neurotoxicity models
22 December 2015 | By Victoria White
The funding is awarded in the context of the Neuratect CRACK IT Challenge to support development of better predictive, high-throughput, animal-free models for neurotoxicity of medicines and chemicals...
article
SSPC – advancing science from molecule to medicine
6 August 2015 | By Synthesis and Solid State Pharmaceutical Centre (SSPC)
Read how the Synthesis and Solid State Pharmaceutical Centre (SSPC) is positioning Ireland as a global hub for advanced pharmaceutical manufacturing...
news
Enterome enters into a microbiome-based development collaboration with AbbVie in Crohn’s disease
12 November 2014 | By Enterome
Collaboration to generate novel diagnostic products to support personalized therapies for microbiome-related diseases...
news
AbbVie announces initiation of pivotal Phase III study of Veliparib (ABT-888) in patients with advanced breast cancer
26 June 2014 | By AbbVie
AbbVie announced the initiation of a Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888)...
news
Biogen Idec and AbbVie announce positive top-line results from Phase 3 study investigating daclizumab high-yield process in multiple sclerosis
16 June 2014 | By Biogen Idec
Biogen Idec and AbbVie announced positive top-line results from the Phase 3 DECIDE clinical trial, designed to evaluate the superiority of once-monthly, subcutaneous daclizumab high-yield process...
news
Abbvie to present detailed results from phase iii studies in patients with chronic hepatitis C at the 2014 International Liver Congress™
24 March 2014 | By AbbVie
AbbVie will present new data from its phase III hepatitis C development program at the 2014 International Liver Congress™...